Naslov
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA

Autori
Grint, D. ; ... ; Begovac, Josip ; ...

Izvornik
Hiv medicine (1464-2662) 14 (2013), 10; 614-623

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
; CD4 Lymphocyte Count/statistics & numerical data; Cohort Studies; Coinfection; Drug Therapy; Combination; Europe/epidemiology; Female; HIV Infections/complications/ drug therapy/virology; Hepatitis C; Chronic/complications/ drug therapy/virology; Humans; Interferon-alpha/therapeutic use; Liver Cirrhosis/ drug therapy/etiology

Sažetak
Objectives All HIV/hepatitis C virus (HCV)-coinfected patients with chronic HCV infection and F2 fibrosis should be considered for HCV therapy. This study aimed to determine the rate of HCV treatment uptake among coinfected patients in Europe. MethodsEuroSIDA patients with viraemic HCV infection were included in the study. Poisson regression was used to identify temporal changes and regional differences in HCV treatment uptake. ResultsA total of 1984 patients were included in the study, with a median follow-up time of 168 months [interquartile range (IQR) 121-204 months]. To date, 501 (25.3%) HIV/HCV-coinfected patients have received HCV therapy. Treatment incidence rose from 0.33 [95% confidence interval (CI) 0.16-0.50] per 100 person-years of follow-up (PYFU) in 1998 to 5.93 (95% CI 4.49-7.38) in 2007, falling to 3.78 (95% CI 2.50-5.07) in 2009. After adjustment, CD4 cell count >350cells/L [incidence rate ratio (IRR) 1.33 (95% CI 1.06-1.67) vs.CD4 count 200-350 cells/L] and F2 liver fibrosis [IRR 1.60 (95% CI 1.14-2.25 ; P=0.0065) vs. <F2 fibrosis] were predictors of anti-HCV treatment initiation. However, 22% of patients who remain untreated for HCV, with fibrosis data available, had F2 fibrosis and should have been considered for treatment, while only 36% of treated patients had F2 fibrosis. ConclusionsAlthough treatment incidence for HCV has increased, there remain a large proportion of patients indicated for treatment who have yet to be treated.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Group Authors: EuroSIDA EuroCoord. Rad je kao predavanje prezentiran na skupu 11th International Congress on Drug Therapy in HIV Infection, održanom u studenom 2012.g., Glasgow, Ujedinjeno Kraljevstvo.

POVEZANOST RADA